Best known globally for its aspirin and locally for its life-saving hemophilia treatments, drug giant Bayer is firming up plans to lead one of biotech's hottest areas with a pioneering new cell therapy manufacturing facility on its fast-changing Berkeley campus.
The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
By Hannah Devlin, Tom Burgis, David Pegg, and Jason Wilson, The Guardian [cites CGS’ Katie Hasson] | 10.18.2024
Aggregated News
A US startup company is offering to help wealthy couples screen their embryos for IQ using controversial technology that raises questions about the ethics of genetic enhancement.
The company, Heliospect Genomics, has worked with more than a dozen couples undergoing...
By David Pegg, Tom Burgis, Hannah Devlin and Jason Wilson, The Guardian | 10.16.2024
Aggregated News
An international network of “race science” activists seeking to influence public debate with discredited ideas on race and eugenics has been operating with secret funding from a multimillionaire US tech entrepreneur.
Undercover filming has revealed the existence of the organisation...
Donald Trump's fascination with genetics, especially his own "good genes" of the white European sort, as well as the "bad genes" of the you-know-which types, has always...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.